source
- Crown Biosciences stays put as $204M Adicon deal falls throughCrown Biosciences looks destined to go unworn for a while longer after its planned $204 million acquisition by China's Adicon fell through.Fierce Biotech · 1d ago↗ source
- FDA clears Roche's Wilserdly pill for certain ER-positive, HER2-negative breast cancersThe U.S. Food and Drug Administration has approved Roche's new oral therapy Wilserdly for a specific group of breast cancer patients. The drug is indicated for adults with estrogen receptor‑positi…